Radiopharm TheranosticsRADX
13F holders, Q1 2026 (March 31)7holders −4
0new positions
4sold out
$0.04avg. 13F price*
At the end of Q1 2026, 7 institutions reported holding Radiopharm Theranostics Ltd. (RADX) in their 13F filings, down 4 from Q4 2025. 0 opened new positions and 4 sold out. The largest holders were Silverarc Capital Management, LLC ($806K), Stonepine Capital Management, LLC ($739K) and HSBC Holdings PLC ($265K).
- Company
- Radiopharm Theranostics Ltd.
- CUSIP
- 75041J101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 4 | $205K |
All 13F filers, Q4 2025 → Q1 2026: 115 shares bought and 231,655 shares sold, net −231,540 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Silverarc Capital Management, LLC | 0.10% | No change | 187,406 | $806K |
| Stonepine Capital Management, LLC | 0.65% | No change | 51,000,000 | $739K |
| HSBC Holdings PLC | 0.00% | Reduce -68.0% | 61,372 | $265K |
| Regal Partners Ltd | 0.01% | Reduce -55.9% | 40,138 | $173K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 16,000 | $69K |
| UBS Group AG | 0.00% | Reduce -79.0% | 3,000 | $13K |
| Rhumbline Advisers | 0.00% | Add +1916.7% | 121 | $519 |
"% of holder's portfolio" is RADX's weight in each manager's 13F, not the share of Radiopharm Theranostics Ltd. the manager owns.